title: [Animal experiments of immunotherapy with ovarian tumor vaccine during lymphopenia induced by chemotherapy.].
abstract: OBJECTIVE
  To explore the mechanisms and effects of adoptive immunotherapy with ovarian cancer vaccine modified by GM-CSF gene which was used after immunologic reconstitution during lymphopenia induced by chemotherapy.
  
  
  METHODS
  Lymphopenia was induced by chemotherapy with cyclophosphamide. The immune reconstituted model was built in rats. The tumor vaccine draining lymph nodes were harvested after the ovarian cancer cells NUTU-19 modified by GM-CSF gene were injected. The effector T cells (T(E)) were got after being stimulated and amplified. Enzyme-linked immunosorbent assay was used to detect the level of interleukin (IL)-2 and IL-4 secreted by T(E). Intracellular cytokine staining was used to determine frequency of tumor-specific T(E). Fluorescence-activated cell sorting (FACS) was used to detect the special cytotoxicity of T(E) killing target cells. The survival period of rats bearing pre-established abdominal ovariam carcinoma after being adoptively transferred by T(E) was observed.
  
  
  RESULTS
  Compared with those in control group, the significant higher levels IL-2 [(65.7 +/- 4.0) pg/ml] and lower levels IL-4 [(277 +/- 49) pg/ml] were observed in chemotherapy-immune reconstitution-vaccine immunization group. The amount of CD(4)(+) T cells secreting interferon-gamma (13.0 +/- 2.1)% were also significantly increased. The rate of the special cytotoxicity of killing T cells (86.5 +/- 1.1)% was markedly improved. The survival period of rats (110 +/- 16) days was increased in chemotherapy-immune reconstitution-vaccine immunization group.
  
  
  CONCLUSIONS
  The combined immunotherapy of chemotherapy-immune reconstitution-tumor vaccine immunotherapy may increase the frequency and function of specific tumor T(E). The specific cytotoxicity is increased and the weak reaction of T(E) to tumor is improved, which showed that this therapy can enhance immune reaction.
authors.affiliation: Department of Obstetrics and Gynecology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
authors.forename: Qi-Ling
authors.initials: QL
authors.lastname: Li
authors.forename: Yun-Ping
authors.initials: YP
authors.lastname: Wang
authors.forename: Shang-Feng
authors.initials: SF
authors.lastname: Gao
authors.forename: Jun
authors.initials: J
authors.lastname: Ma
authors.forename: Cai-Xia
authors.initials: CX
authors.lastname: Feng
authors.forename: Yue-Ling
authors.initials: YL
authors.lastname: Wang
mesh_terms: D032761:Animal Experimentation; D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2; D008231:Lymphopenia; D010051:Ovarian Neoplasms / Q000188:drug therapy
chemical_list: D019496:Cancer Vaccines; D007376:Interleukin-2